HUYPS-1

HUYPS-1 is an orally administered investigational product developed by Sinew Pharma and evaluated in a completed randomized, open-label, single-dose, two-period crossover Phase I pharmacokinetic study in healthy volunteers. The registered study associated the product with metabolic dysfunction-associated steatohepatitis and tested one-tablet versus nine-tablet oral doses. The trial record states that each tablet contained 100 mg mannitol and 100 mg sucralose, described in the record as commonly used pharmaceutical excipients; however, publicly available trial information does not establish an additional active ingredient, a defined molecular structure beyond these stated constituents, or a specific therapeutic target and mechanism for HUYPS-1.

Other names

deuterated pioglitazoneH-Sinew